European equities traded in the US as American depositary receipts were lower late Thursday morning, declining 0.1% to 1,589.29 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biotech firm Evaxion (EVAX) and biopharmaceutical company DBV Technologies (DBVT), which rose 5.7% and 4.6% respectively. They were followed by lender Banco Bilbao Vizcaya Argentaria (BBVA) and biopharmaceutical company argenx (ARGX), which were up 2.9% and 2.7% respectively.

The decliners from continental Europe were led by semiconductor company Sequans Communications (SQNS) and software firm SAP (SAP), which dropped 3.5% and 3.3% respectively. They were followed by internet browser company Opera (OPRA) and biopharmaceutical company Grifols (GRFS), which lost 3% and 2.7% respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical company Bicycle Therapeutics (BCYC) and pharmaceutical company AstraZeneca (AZN), which advanced 4.4% and 3.3% respectively. They were followed by biopharmaceutical company Amarin (AMRN) and pharmaceutical company Silence Therapeutics (SLN), which increased 2% and 2.6% respectively.

The decliners from the UK and Ireland were led by medical device maker Smith & Nephew (SNN) and alcoholic beverage company Diageo (DEO), which fell 12% and 6.5% respectively. They were followed by biotech firm Trinity Biotech (TRIB) and educational publisher Pearson (PSO), which were down 4.2% and 3.4% respectively.